{"denoms":[{"counts":[{"groupId":"BG000","value":"13"}],"units":"Participants"}],"groups":[{"description":"All patients will receive Carfilzomib\n\nCarfilzomib: During Cycle 1, patients will receive either 20 mg/m2 on days 1,2 (if the subject has not received carfilzomib as part another clinical trial within the last 4 weeks) or 56 mg/m2 (if the subject is enrolling in the present study after progression of disease on carfilzomib within the last month - for example subjects enrolled in CMAP compassionate use carfilzomib). Thereafter, all subjects will receive 56 mg/m2 for the remaining doses given Cycle 1 Day 8 onwards. Each cycle is 28 days.","id":"BG000","title":"Carfilzomib"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"49","upperLimit":"75","value":"62.9"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age >65 years","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"2"}],"description":"The Eastern Cooperative Oncology Group (ECOG) measures level of functioning in terms of daily living abilities:\n\n0\\. - Fully active, able to carry on all pre-disease performance without restriction\n\n1. \\- Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work\n2. \\- Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours","paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG Performance Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Stage 1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Stage 2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Stage 3"}],"description":"The International Staging System (ISS): The ISS is based on the assessment of two blood test results: beta 2-microglobulin (ß2-M) and albumin.\n\nStage I - ß2-M \\< 3.5 mg/dL and albumin =3.5 g/dL Stage II - Neither stage I nor stage III Stage III - ß2-M ≥ 5.5 mg/L","paramType":"COUNT_OF_PARTICIPANTS","title":"ISS Staging","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"title":"IgG"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"IgA"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"IgM"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"none"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Immunoglobulin subtype","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"K"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"L"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Light-chain subtype","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"Normal"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"Any abnormality"}],"description":"Fluorescence in situ hybridization (FISH), a molecular cytogenetic technique that tags genetic material with fluorescent molecules. FISH is useful for identifying chromosomes and parts of chromosomes, deciphering chromosome rearrangements, detecting chromosome abnormalities, and detecting and mapping genes.","paramType":"COUNT_OF_PARTICIPANTS","title":"FISH","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"2","upperLimit":"10","value":"7"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Prior therapies since diagnosis","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"2","upperLimit":"10","value":"5"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Number of prior regimens","unitOfMeasure":"prior regimens"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"Dexamethasone : Exposed"},{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"Dexamethasone : Refractory"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"Thalidomide : Exposed"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Thalidomide : Refractory"},{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"Lenalidomide : Exposed"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"Lenalidomide : Refractory"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"Pomalidomide : Exposed"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"Pomalidomide : Refractory"},{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"Bortezomib : Exposed"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"Bortezomib : Refractory"}],"paramType":"NUMBER","title":"Prior therapy","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Prior Autologous Stem Cell Transplant","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"Carfilzomib Regimen Combination"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"Weekly 40 mg DEX"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Pomalidomide, DEX"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Cyclophosphamide, DEX"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Ibrutinib, DEX"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Bendamustine"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Carfilzomib Regimen Combination","unitOfMeasure":"Participants"}]}